REDWOOD CITY, Calif. — Ashvattha Therapeutics, a biotech company focused on novel dendrimer-based therapies targeting unmet medical needs in ocular, inflammatory diseases, and oncology, has been selected to present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, held June 22-24, 2020.
Full details of the virtual presentation are as follows:
Abstract Title: Selective targeting of immunosuppressive tumor macrophage from systemic administration
Abstract Number: 2595
Poster Session: Targeting the Tumor Microenvironment
Poster Number: 679
Location: AACR Virtual Annual Meeting II at www.aacr.org
“We’re excited to present this data at AACR 2020, which is another example of the ability of our hydroxyl dendrimer platform to target reactive macrophages. By selectively targeting reactive tumor associated macrophages, we are able to modulate the tumor microenvironment to enable innate immune responses to the tumor. We have demonstrated that chemically coupling drugs to the hydroxyl dendrimer substantially reduces their toxicity while maintaining or improving their efficacy due to the selective targeting. Ashvattha is developing a pipeline of hydroxyl dendrimers chemically conjugated to proprietary compounds to drive pro-inflammatory responses and to block angiogenesis in tumors. We look forward to sharing our preclinical efficacy and toxicology results on our lead compounds at a future oncology conference,” said Jeffrey Cleland, Ph.D., Chairman, CEO & President at Ashvattha Therapeutics.
The poster will be available for reviewing on June 22, the first day of the AACR Virtual Annual Meeting II. The abstract will also be published in an online-only Proceedings supplement to the AACR journal Cancer Research after the completion of the AACR Virtual Annual Meeting II.
Video presentations will be available for viewing on demand through the virtual meeting platform. For more information, visit the AACR Virtual Annual Meeting II page at www.aacr.org.
About Ashvattha Therapeutics
Ashvattha Therapeutics holds the exclusive rights to a novel hydroxyl dendrimer technology developed at Johns Hopkins University enabling a new class of targeted therapies previously unachievable with traditional drug moieties. Ashvattha are commercializing the technology through new entities established to develop therapeutic opportunities within specific fields and enabled through the use of our dendrimer platform. For more information, visit: www.avttx.com
Contacts
Investors:
Matt Brewer
Ashvattha Therapeutics
matt@avttx.com
303-717-9446
Media:
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744